Related Experiment Video
Updated: Jan 7, 2026
10:46
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
Published on: May 26, 2015
13.7K
Anticoagulation for atrial fibrillation and stroke prevention
1Department of Neurology, Hvidovre Hospital, University of Copenhagen, Denmark.
Neuroepidemiology
|January 1, 1993
Summary
Anticoagulation therapy significantly reduces stroke risk by 65% in patients with nonvalvular atrial fibrillation (NVAF). However, it also increases the risk of intracerebral hemorrhage compared to placebo.
Area of Science:
- Cardiology
- Neurology
- Geriatrics
Background:
- Nonvalvular atrial fibrillation (NVAF) prevalence increases with age, affecting over 4% of individuals older than 80.
- NVAF patients face a 3-8% annual stroke incidence, 5-7 times higher than those in sinus rhythm.
Purpose of the Study:
- To evaluate the efficacy and risks of anticoagulation therapy for stroke prevention in NVAF patients.
- To identify key risk factors for stroke in individuals with NVAF.
Main Methods:
- Review of five independent studies on stroke prevention in NVAF.
- Analysis of anticoagulation therapy outcomes, including stroke risk reduction and hemorrhage risk.
- Identification of stroke risk factors through individual study data.
Main Results:
- Anticoagulation therapy demonstrated a 65% stroke risk reduction in NVAF patients.
- Warfarin therapy was associated with a 0.3% annual intracerebral hemorrhage risk, versus 0.1% in placebo.
- Aspirin showed a 42% risk reduction in one study, but a nonsignificant effect in another.
Conclusions:
- Anticoagulation is effective for stroke prevention in NVAF, but carries an increased risk of hemorrhage.
- Risk factors for stroke in NVAF include advanced age, hypertension, heart failure, and prior thromboembolism.
Related Concept Videos
01:26Atherosclerosis III: Management
290
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
290
01:30Venous Thrombosis IV: Nursing Management
175
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
175
01:29Venous Thrombosis III: Interprofessional Care
254
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
254
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.0K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.0K